CHCWM – Cancer & Hematology Centers of West Michigan

GENMAB (GCT1046-04)

GENMAB (GCT1046-04) A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor PI: Dr. Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at

Helsinn (ANAM)

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in adult patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Principal Investigator: Dr. Yuanbin Chen For more information on this trial, read its profile on clinicaltrials.gov here.

PAL-E602-001 (Palleon)

Description:  A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers Mechanism of Action:  cleaves off immunosuppressive sialoglycans from immune and tumor cells to enhance antitumor immunity Target Patient Population:   Melanoma,

C4161001 (Pfizer)

Description:  Phase 1/2a Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of PF-07104091 as a Single Agent and in Combination Therapy. Mechanism of Action:  CDK2 inhibitor Target Patient Population:   Small cell Lung Cancer, Platinum Resistant Ovarian, Non-small cell Lung Cancer; in combination with palbociclib and fulvestrant for HR+ HER2-

C4391001 ( Pfizer)

Description:  A Phase 1/1B Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07220060 as a Single Agent and As Part of Combination Therapy In Participants With Advanced Solid Tumors. Mechanism of Action:  CDK4 inhibitor Target Patient Population:   Metastatic Breast Cancer, NSCLC (adeno), Prostate cancer, Colorectal cancer, Liposarcoma and tumor types with CDK4

SGN B7H4V-001 (Seagen, Inc.)

Description:  A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors Mechanism of Action:  .antibody drug conjugate to B7H4V.  B7H4 is an immune checkpoint protein present on cancer cells Target Patient Population:  Ovarian, Primary peritoneal or Fallopian, Breast (HER2-, HR+), Triple Negative Breast, Endometrial, Squamous Non Small Cell Lung, Cholangiocarcinoma, Gallbladder cancers. Study Design:  Drug

Sanofi (CARMEN-LC03)

Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors Principal Investigator: Dr. Eric Santos For more information on this trial, read its profile on clinicaltrials.gov here.

SY-5609-101 (Syros)

SY-5609-101 (Syros) Description:  A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Select Advanced Solid Tumors Mechanism of Action:  CDK7 inhibitor Target Patient Population:   Metastatic breast cancer, ovarian, lung, colorectal or any malignancy with mutation of RB1, CDKN1A/CDKN2A, amplification of CCNE1, CCND1, CCND2, CDK4 or CDK6); in combination with